Naselsky D P, Ashton D, Ruffolo R R, Hieble J P
Department of Pharmacology, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA.
J Pharmacol Exp Ther. 2001 Jul;298(1):219-25.
The recombinant alpha2-adrenoceptors, designated as alpha2a and alpha2d, have highly similar amino acid sequences, but distinct pharmacological properties. It has been suggested that these two receptor subtypes are species orthologs, since the alpha2-adrenoceptors of a given species have pharmacological characteristics corresponding to either the alpha2a- (human, pig) or alpha2d- (rat, mouse, guinea pig, cow) adrenoceptor. Radioligand binding assays in rabbit adipocyte suggest alpha2D-adrenoceptor pharmacology. However, functional studies examining prejunctional alpha2-adrenoceptors in several tissues pharmacologically define the receptor of the rabbit as an alpha2A-adrenoceptor rather than an alpha2D-adrenoceptor. We characterized the alpha2-adrenoceptor of rabbit adipocyte and platelet, comparing the ability of norepinephrine and 13 adrenoceptor antagonists to inhibit the binding of [3H]RX821002 with the affinity of these drugs for the human alpha2a-adrenoceptor or the rat alpha2d-adrenoceptor. Pharmacological characteristics of the adipocyte and platelet receptor were very similar, with an excellent correlation between pK(i) values (r2 = 0.95, slope of regression = 1.01). Drug affinities for both platelet and adipocyte receptors correlated better with the alpha2a-adrenoceptor (r2 = 0.68-0.77) than with the alpha2d-adrenoceptor (r2 = 0.37-0.38). Despite the relatively low affinity of the rabbit adipocyte alpha2-adrenoceptor for yohimbine and rauwolscine, this receptor, as well as the platelet receptor, have alpha2A-adrenoceptor pharmacology. Subtle differences in the alpha2-adrenoceptor binding characteristics of these native rabbit tissues compared with the recombinant human alpha2a-adrenoceptor may result either from minor differences in the sequence of human and rabbit alpha2a-adrenoceptors or from differences in the environment to which native and recombinant receptors are exposed.
重组α2-肾上腺素能受体,命名为α2a和α2d,具有高度相似的氨基酸序列,但药理学特性不同。有人提出这两种受体亚型是物种直系同源物,因为给定物种的α2-肾上腺素能受体具有与α2a-(人类、猪)或α2d-(大鼠、小鼠、豚鼠、牛)肾上腺素能受体相对应的药理学特征。兔脂肪细胞中的放射性配体结合试验表明存在α2D-肾上腺素能受体药理学特性。然而,在多个组织中对突触前α2-肾上腺素能受体进行的功能研究从药理学角度将兔的受体定义为α2A-肾上腺素能受体而非α2D-肾上腺素能受体。我们对兔脂肪细胞和血小板的α2-肾上腺素能受体进行了表征,比较了去甲肾上腺素和13种肾上腺素能拮抗剂抑制[3H]RX821002结合的能力以及这些药物对人α2a-肾上腺素能受体或大鼠α2d-肾上腺素能受体的亲和力。脂肪细胞和血小板受体的药理学特性非常相似,pK(i)值之间具有良好的相关性(r2 = 0.95,回归斜率 = 1.01)。药物对血小板和脂肪细胞受体的亲和力与α2a-肾上腺素能受体的相关性更好(r2 = 0.68 - 0.77),而与α2d-肾上腺素能受体的相关性较差(r2 = 0.37 - 0.38)。尽管兔脂肪细胞α2-肾上腺素能受体对育亨宾和萝芙木碱的亲和力相对较低,但该受体以及血小板受体具有α2A-肾上腺素能受体药理学特性。与重组人α2a-肾上腺素能受体相比,这些天然兔组织的α2-肾上腺素能受体结合特性存在细微差异,这可能是由于人和兔α2a-肾上腺素能受体序列的微小差异,或者是由于天然受体和重组受体所处环境的差异所致。